Tagged with IT

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Switzerland Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.…

Switzerland Interpharma’s Dr René P. Buholzer highlights the key lessons that Switzerland’s innovative pharmaceutical industry has taken from the COVID-19 pandemic, the challenges inherent in the country’s two upcoming cost containment packages, and progress made on the circuitous journey towards a more standardised national health data ecosystem.   Switzerland wants to…

Turkey Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials, localization and an operational hub overseeing 75 countries. After almost two decades working with the Danish diabetes and obesity giant,…

Switzerland AstraZeneca’s recently arrived Switzerland country president, Katrien de Vos, gives her first impressions of the Swiss market and how she hopes to build upon the affiliate’s strong performance. de Vos also touches on access challenges (and how to surmount them) as well as AstraZeneca Switzerland’s role in bringing the company’s…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…

Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm.   COVID has led…

Switzerland The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI) by 38 percent and NASDAQ Biotech by 46 per cent between 2015 and 2020. Key listings include Kuros Biosciences, Idorsia, Polyphor, ObsEva, and IGEA Pharma Made with Visme Infographic Maker   To read more about the Swiss biotech investment…